placeholder
and
and

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Proceed order?

Export
Filter
Document type
Language
Year
  • 1
    Language: English
    In: Journal of clinical oncology, 2012-06-10, Vol.30 (17), p.2112-2118
    Description: We compared two chemotherapy regimens that included methotrexate (MTX), cisplatin (CDP), and doxorubicin (ADM) with or without ifosfamide (IFO) in patients with nonmetastatic osteosarcoma of the extremity. Patients age ≤ 40 years randomly received regimens with the same cumulative doses of drugs (ADM 420 mg/m(2), MTX 120 g/m(2), CDP 600 mg/m(2), and IFO 30 g/m(2)) but with different durations (arm A, 44 weeks; arm B, 34 weeks). IFO was given postoperatively when pathologic response to MTX-CDP-ADM was poor (arm A) or given in the primary phase of chemotherapy with MTX-CDP-ADM (arm B). End points of the study included pathologic response to preoperative chemotherapy, toxicity, and survival. Given the feasibility of accrual, the statistical plan only permitted detection of a 15% difference in 5-year overall survival (OS). From April 2001 to December 2006, 246 patients were enrolled. Two hundred thirty patients (94%) underwent limb salvage surgery (arm A, 92%; arm B, 96%; P = .5). Chemotherapy-induced necrosis was good in 45% of patients (48% in arm A, 42% in arm B; P = .3). Four patients died of treatment-related toxicity (arm A, n = 1; arm B, n = 3). A significantly higher incidence of hematologic toxicity was reported in arm B. With a median follow-up of 66 months (range, 1 to 104 months), 5-year OS and event-free survival (EFS) rates were not significantly different between arm A and arm B, with OS being 73% (95% CI, 65% to 81%) in arm A and 74% (95% CI, 66% to 82%) in arm B and EFS being 64% (95% CI, 56% to 73%) in arm A and 55% (95% CI, 46% to 64%) in arm B. IFO added to MTX, CDP, and ADM from the preoperative phase does not improve the good responder rate and increases hematologic toxicity. IFO should only be considered in patients who have a poor histologic response to MTX, CDP, and ADM.
    Subject(s): Biological and medical sciences ; Medical sciences ; Diseases of the osteoarticular system ; Tumors of striated muscle and skeleton ; Tumors ; Osteosarcoma - drug therapy ; Femur - pathology ; Humans ; Child, Preschool ; Male ; Tibia - pathology ; Cisplatin - administration & dosage ; Humerus - pathology ; Disease-Free Survival ; Ifosfamide - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Chemotherapy, Adjuvant - methods ; Adolescent ; Adult ; Female ; Methotrexate - administration & dosage ; Bone Neoplasms - drug therapy ; Child ; Doxorubicin - administration & dosage
    ISSN: 0732-183X
    E-ISSN: 1527-7755
    Source: Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
    Source: © ProQuest LLC All rights reserved〈img src="https://exlibris-pub.s3.amazonaws.com/PQ_Logo.jpg" style="vertical-align:middle;margin-left:7px"〉
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Language: English
    In: Molecular cancer, 2009-12-10, Vol.8 (1), p.118-118
    Description: Osteosarcoma (OS) is the most common primary bone tumour in children and young adults. Despite improved prognosis, metastatic or relapsed OS remains largely incurable and no significant improvement has been observed in the last 20 years. Therefore, the search for alternative agents in OS is mandatory. We investigated phospho-ERK 1/2, MCL-1, and phospho-Ezrin/Radixin/Moesin (P-ERM) as potential therapeutic targets in OS. Activation of these pathways was shown by immunohistochemistry in about 70% of cases and in all OS cell lines analyzed. Mutational analysis revealed no activating mutations in KRAS whereas BRAF gene was found to be mutated in 4/30 OS samples from patients. Based on these results we tested the multi-kinase inhibitor sorafenib (BAY 43-9006) in preclinical models of OS. Sorafenib inhibited OS cell line proliferation, induced apoptosis and downregulated P-ERK1/2, MCL-1, and P-ERM in a dose-dependent manner. The dephosphorylation of ERM was not due to ERK inhibition. The downregulation of MCL-1 led to an increase in apoptosis in OS cell lines. In chick embryo chorioallantoic membranes, OS supernatants induced angiogenesis, which was blocked by sorafenib and it was also shown that sorafenib reduced VEGF and MMP2 production. In addition, sorafenib treatment dramatically reduced tumour volume of OS xenografts and lung metastasis in SCID mice. In conclusion, ERK1/2, MCL-1 and ERM pathways are shown to be active in OS. Sorafenib is able to inhibit their signal transduction, both in vitro and in vivo, displaying anti-tumoural activity, anti-angiogenic effects, and reducing metastatic colony formation in lungs. These data support the testing of sorafenib as a potential therapeutic option in metastatic or relapsed OS patients unresponsive to standard treatments.
    Subject(s): Niacinamide - analogs & derivatives ; Osteosarcoma - drug therapy ; Vascular Endothelial Growth Factor A - biosynthesis ; Cytoskeletal Proteins - antagonists & inhibitors ; Apoptosis - drug effects ; Humans ; Extracellular Signal-Regulated MAP Kinases - antagonists & inhibitors ; Male ; Antineoplastic Agents - therapeutic use ; Benzenesulfonates - therapeutic use ; Phenylurea Compounds ; Extracellular Signal-Regulated MAP Kinases - metabolism ; Vascular Endothelial Growth Factor A - antagonists & inhibitors ; Proto-Oncogene Proteins c-bcl-2 - metabolism ; Benzenesulfonates - pharmacology ; Neoplasm Metastasis - prevention & control ; Osteosarcoma - blood supply ; Cytoskeletal Proteins - metabolism ; Female ; Neovascularization, Pathologic - prevention & control ; Antineoplastic Agents - pharmacology ; Matrix Metalloproteinase 2 - biosynthesis ; Osteosarcoma - metabolism ; Pyridines - therapeutic use ; Down-Regulation - drug effects ; Cell Division - drug effects ; Animals ; Myeloid Cell Leukemia Sequence 1 Protein ; Cell Line, Tumor ; Matrix Metalloproteinase Inhibitors ; Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors ; Mice ; Pyridines - pharmacology ; Osteosarcoma - pathology ; Development and progression ; Diagnosis ; Drug therapy ; Osteosarcoma ; Risk factors ; Index Medicus
    ISSN: 1476-4598
    E-ISSN: 1476-4598
    Source: BioMedCentral Open Access
    Source: Academic Search Ultimate
    Source: PubMed Central
    Source: © ProQuest LLC All rights reserved〈img src="https://exlibris-pub.s3.amazonaws.com/PQ_Logo.jpg" style="vertical-align:middle;margin-left:7px"〉
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Language: English
    In: Annals of surgical oncology, 2010-01, Vol.17 (1), p.211-219
    Description: Chordoma is a rare tumor, and its natural history is still not well known.All patients affected by localized chordoma surgically treated at Istituto Ortopedico Rizzoli, Bologna, and Istituto Nazionale Tumori, Milan, Italy, between 1980 and 2008 were reviewed. Local recurrence, distant metastasis, and overall survival (OS) were analyzed both from time of diagnosis and from time of local recurrence/distant metastasis. A multivariable analysis to identify independent prognostic factors was carried out.A total of 138 consecutive patients were identified (sacrum 78%, lumbar spine 15%, cervical-dorsal spine 7%). Of these, 130 underwent surgical resection. Median follow-up was 142 months. The 5- and 10-year OS, local relapse-free survival (LRFS), and distant relapse-free survival (DRFS) were, respectively, 78% and 54%, 52% and 33%, and 86% and 72%. Size was an independent prognostic factor for OS (P value 〈 .001), LRFS (P value: .038), and DRFS (P value: .004), while surgical margins independently predicted LRFS (P value: .003) with a trend for OS. The 5- and 10-year OS, LRFS, and DRFS after the first local relapse were 50% and 26%, 47% and 31%, and 64% and 61%. The size of the recurrence and quality of surgical margins did not influence postrelapse OS. The 5-year OS after the second local relapse was 19%. 22% of patients developed distant metastases with a 5-year post-metastases OS of 33%.Tumor size and surgical margins affected outcome only on initial presentation. However, wide surgery was feasible in a minority of cases. Most patients died of local–regional disease even when metastases occurred. Indeed, long-term prognosis was such that disease-free survival at 10 years was only 26%.
    Subject(s): Oncology ; Medicine & Public Health ; Surgical Oncology ; Surgery ; Sacrum - pathology ; Chordoma - surgery ; Spinal Neoplasms - pathology ; Humans ; Middle Aged ; Male ; Spinal Neoplasms - mortality ; Survival Rate ; Treatment Outcome ; Neoplasm Recurrence, Local - mortality ; Neoplasm Recurrence, Local - surgery ; Chordoma - pathology ; Neoplasm Recurrence, Local - pathology ; Sacrum - surgery ; Female ; Aged ; Retrospective Studies ; Chordoma - mortality ; Spinal Neoplasms - surgery ; Tumors, Embryonal ; Care and treatment ; Metastasis ; Analysis ; Index Medicus
    ISSN: 1068-9265
    E-ISSN: 1534-4681
    Source: Alma/SFX Local Collection
    Source: © ProQuest LLC All rights reserved〈img src="https://exlibris-pub.s3.amazonaws.com/PQ_Logo.jpg" style="vertical-align:middle;margin-left:7px"〉
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    Language: English
    In: Virchows Archiv : an international journal of pathology, 2009-11, Vol.455 (5), p.397-411
    Description: Ewing's sarcoma (ES)/peripheral neuroectodermal tumor (PNET) are malignant neoplasms affecting children and young adults. We performed a study to typify the histological diversity and evaluate antibodies that may offer diagnostic/prognostic support. In total, 415 cases of genetically confirmed paraffin-embedded ES/PNET were analyzed on whole sections and in tissue microarrays. This study confirms the structural heterogeneity of ES/PNET, distinguishing three major subtypes: conventional ES (280 cases); PNET (53 cases); and atypical ES/PNET (80), including large cells, vascular-like patterns, spindle pattern, and adamantinoma-like configuration. All cases presented positivity for at least three of the four tested antibodies (CD99, FLI1, HNK1, and CAV1). CAV1 appeared as a diagnostic immunomarker of ES/PNET being positive in CD99-negative cases. Hence, the immunohistochemical analysis confirmed the diagnostic value of all four antibodies, which together cover more than 99% of the tumors, independently of the histological variety. The univariate analysis for survival revealed atypical ES as the only histological parameter apparently associated with less favorable clinical outcome, particularly in the subgroup of patients treated with surgery. In conclusion, the diagnosis of atypical ES is a challenge for the pathologist and needs support from molecular techniques to perform an optimal differential diagnosis with other small round cell tumors.
    Subject(s): Immunohistochemistry ; Neuroectodermal Tumors, Primitive, Peripheral - pathology ; Prognosis ; Antigens, CD - biosynthesis ; Humans ; Middle Aged ; Sarcoma, Ewing - pathology ; Antibodies ; Child, Preschool ; Infant ; Male ; Proto-Oncogene Protein c-fli-1 - biosynthesis ; CD57 Antigens - biosynthesis ; Bone Neoplasms - pathology ; Bone Neoplasms - metabolism ; Young Adult ; Aged, 80 and over ; Adult ; Female ; Child ; Sarcoma, Ewing - metabolism ; Biomarkers, Tumor - analysis ; Cell Adhesion Molecules - biosynthesis ; Kaplan-Meier Estimate ; Neuroectodermal Tumors, Primitive, Peripheral - metabolism ; In Situ Hybridization, Fluorescence ; Caveolin 1 - biosynthesis ; Disease Progression ; 12E7 Antigen ; Adolescent ; Aged ; Viral antibodies ; Oncology, Experimental ; Research ; Universities and colleges ; Ewing's sarcoma ; Cancer ; Index Medicus
    ISSN: 0945-6317
    E-ISSN: 1432-2307
    Source: Alma/SFX Local Collection
    Source: © ProQuest LLC All rights reserved〈img src="https://exlibris-pub.s3.amazonaws.com/PQ_Logo.jpg" style="vertical-align:middle;margin-left:7px"〉
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    Language: English
    In: Skeletal radiology, 2012-12, Vol.41 (12), p.1495-1507
    Description: The classification of vascular bone tumors remains challenging, with considerable morphological overlap spanning across benign to malignant categories. The vast majority of both benign and malignant vascular tumors are readily diagnosed based on their characteristic histological features, such as the formation of vascular spaces and the expression of endothelial markers. However, some vascular tumors have atypical histological features, such as a solid growth pattern, epithelioid change, or spindle cell morphology, which complicates their diagnosis. Pathologically, these tumors are remarkably similar, which makes differentiating them from each other very difficult. For this rare subset of vascular bone tumors, there remains considerable controversy with regard to the terminology and the classification that should be used. Moreover, one of the most confusing issues related to vascular bone tumors is the myriad of names that are used to describe them. Because the clinical behavior and, consequently, treatment and prognosis of vascular bone tumors can vary significantly, it is important to effectively and accurately distinguish them from each other. Upon review of the nomenclature and the characteristic clinicopathological, radiographic and genetic features of vascular bone tumors, we propose a classification scheme that includes hemangioma, hemangioendothelioma, angiosarcoma, and their epithelioid variants.
    Subject(s): Pathology ; Hemangioendothelioma ; Hemangioma ; Medicine & Public Health ; Orthopedics ; Epithelioid hemangioendothelioma ; Epithelioid hemangioma ; Vascular bone tumors ; Nuclear Medicine ; Imaging / Radiology ; Angiosarcoma ; Epithelioid angiosarcoma ; Diagnostic Imaging - methods ; Neoplasms, Vascular Tissue - classification ; Bone Neoplasms - diagnosis ; Neoplasms, Vascular Tissue - diagnosis ; Bone Neoplasms - classification ; Humans ; Index Medicus
    ISSN: 0364-2348
    E-ISSN: 1432-2161
    Source: Alma/SFX Local Collection
    Source: © ProQuest LLC All rights reserved〈img src="https://exlibris-pub.s3.amazonaws.com/PQ_Logo.jpg" style="vertical-align:middle;margin-left:7px"〉
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    Language: English
    In: Clinical orthopaedics and related research, 2008-09, Vol.466 (9), p.2081-2091
    Description: The unpredictable behavior of giant cell tumor (GCT) parallels its controversial histogenesis. Multinucleated giant cells, stromal cells, and CD68+ monocytes/macrophages are the three elements that interact in GCT. We compared the ability of stromal cells and normal mesenchymal stromal cells to differentiate into osteoblasts. Stromal cells and mesenchymal cells had similar proliferation rates and lifespans. Although stromal cells expressed early osteogenic markers, they were unable to differentiate into osteoblasts but they did express intracellular adhesion molecule-1, a marker of bone-lining cells. They were unable to form clones in a semisolid medium and unable to promote osteoclast differentiation, although they exerted a strong chemotactic effect on osteoclast precursors. Stromal cells may be either immature proliferating osteogenic elements or specialized osteoblast-like cells that fail to show neoplastic features but can induce the differentiation of osteoclast precursors. They might be secondarily induced to proliferate by a paracrine effect induced by monocyte-macrophages and/or giant cells. The increased number of giant cells in GCT may be secondary to an autocrine circuit mediated by the receptor activator of nuclear factor kB.
    Subject(s): Surgical Orthopedics ; Medicine & Public Health ; Sports Medicine ; Surgery ; Orthopedics ; Conservative Orthopedics ; Medicine/Public Health, general ; Cell Proliferation ; Stromal Cells - pathology ; Coculture Techniques ; Humans ; Hyperplasia ; Middle Aged ; Male ; Bone Neoplasms - pathology ; Giant Cell Tumor of Bone - pathology ; Adolescent ; Adult ; Female ; Cell Transformation, Neoplastic - pathology ; Cell Differentiation - physiology ; Index Medicus ; Abridged Index Medicus ; Symposium ; Molecular Genetics in Sarcoma
    ISSN: 0009-921X
    E-ISSN: 1528-1132
    Source: PubMed Central
    Source: Alma/SFX Local Collection
    Source: © ProQuest LLC All rights reserved〈img src="https://exlibris-pub.s3.amazonaws.com/PQ_Logo.jpg" style="vertical-align:middle;margin-left:7px"〉
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    Language: English
    In: Clinical cancer research, 2009-05-15, Vol.15 (10), p.3550-3556
    Description: Purpose: The germ-line polymorphisms TP53 Arg72Pro and MDM2 SNP309 T〉G are risk factors for tumor development and affect response to chemotherapy and survival in several cancers, but their prognostic and predictive value in patients with high-grade osteosarcomas is not yet defined. The purpose of this study was to investigate the effect of the TP53 Arg72Pro and the MDM2 SNP309 on the risk of osteosarcoma development and survival. Experimental Design: The relative risk to develop osteosarcomas and the overall survival associated to TP53 Arg72Pro and MDM2 SNP309 polymorphisms were investigated in 201 patients. Correlations with event-free survival (EFS) were analyzed in a homogeneous subgroup of 130 patients with high-grade osteosarcomas of the limbs, nonmetastatic at diagnosis, which underwent neoadjuvant chemotherapy. Results: Multivariate analysis showed that the MDM2 polymorphism T309G was associated with an increased risk of developing osteosarcomas [GG versus TT; odds ratio, 2.09; 95% confidence interval (95% CI), 1.15-3.78]. A case/control gender approach evidenced a significant increased risk only for female osteosarcoma patients (GG versus TT; odds ratio, 4.26; 95% CI, 1.61-11.25). Subjects carrying the TP53 Arg72Pro polymorphism were found to have a significantly increased death risk (Pro/Pro versus Arg/Arg; hazard ratio, 2.90; 95% CI, 1.28-6.66). In the subgroup of 130 high-grade osteosarcomas, the TP53 Arg72Pro was an independent marker of EFS (Pro/Pro versus Arg/Arg; hazard ratio, 2.67; 95% CI, 1.17-6.11). Conclusion: The study provides evidence supporting the association of MDM2 SNP309 with high-grade osteosarcoma risk in females and shows that TP53 Arg72Pro has a prognostic value for overall survival and EFS in osteosarcoma patients.
    Subject(s): MDM2 ; TP53 ; osteosarcomas ; Biological and medical sciences ; Medical sciences ; Antineoplastic agents ; Pharmacology. Drug treatments ; Diseases of the osteoarticular system ; Tumors of striated muscle and skeleton ; Multivariate Analysis ; Proto-Oncogene Proteins c-mdm2 - genetics ; Gene Frequency ; Humans ; Middle Aged ; Risk Factors ; Genotype ; Male ; Tumor Suppressor Protein p53 - genetics ; Young Adult ; Adolescent ; Survival Analysis ; Aged, 80 and over ; Adult ; Female ; Aged ; Polymorphism, Single Nucleotide ; Osteosarcoma - genetics ; Child ; Osteosarcoma - pathology ; Amino Acid Substitution ; Index Medicus
    ISSN: 1078-0432
    E-ISSN: 1557-3265
    Source: HighWire Press (Free Journals)
    Source: Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
    Source: © ProQuest LLC All rights reserved〈img src="https://exlibris-pub.s3.amazonaws.com/PQ_Logo.jpg" style="vertical-align:middle;margin-left:7px"〉
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    Language: English
    In: BMC cancer, 2011-11-02, Vol.11 (1), p.472-472
    Description: The polycomb transcription factor Yin Yang 1 (YY1) overexpression can be causally implicated in experimental tumor growth and metastasization. To date, there is no clinical evidence of YY1 involvement in outcome of patients with osteosarcoma. Prognosis of osteosarcoma is still severe and only few patients survive beyond five years. We performed a prospective immunohistochemistry analysis to correlate YY1 immunostaining with metastatic development and survival in a selected homogeneous group of patients with osteosarcoma. We studied 41 patients suffering from osteosarcoma (stage II-IVa). Multivariate analysis was performed using Cox proportional hazard regression to evaluate the correlation between YY1 expression and both metastasis development and mortality. YY1 protein is not usually present in normal bone; in contrast, a high number of patients (61%) showed a high score of YY1 positive cells (51-100%) and 39% had a low score (10-50% positive cells). No statistical difference was found in histology, anatomic sites, or response to chemotherapy between the two degrees of YY1 expression. Cox regression analysis demonstrated that the highest score of YY1 expression was predictive of both low metastasis-free survival (HR = 4.690, 95%CI = 1.079-20.396; p = 0.039) and poor overall survival (HR = 8.353, 95%CI = 1.863-37.451 p = 0.006) regardless of the effects of covariates such as age, gender, histology and chemonecrosis. Overexpression of YY1 in primary site of osteosarcoma is associated with the occurrence of metastasis and poor clinical outcome.
    Subject(s): Immunohistochemistry ; Multivariate Analysis ; Prognosis ; Prospective Studies ; Bone Neoplasms - therapy ; Humans ; Middle Aged ; Male ; YY1 Transcription Factor - metabolism ; Neoplasm Proteins - metabolism ; Bone Neoplasms - metabolism ; Disease-Free Survival ; Analysis of Variance ; Adult ; Female ; Osteosarcoma - secondary ; Osteosarcoma - therapy ; Osteosarcoma - metabolism ; Prevention ; Care and treatment ; Transcription factors ; Osteosarcoma ; Physiological aspects ; Genetic aspects ; Metastasis ; Research ; Risk factors ; Index Medicus
    ISSN: 1471-2407
    E-ISSN: 1471-2407
    Source: BioMedCentral Open Access
    Source: Academic Search Ultimate
    Source: PubMed Central
    Source: © ProQuest LLC All rights reserved〈img src="https://exlibris-pub.s3.amazonaws.com/PQ_Logo.jpg" style="vertical-align:middle;margin-left:7px"〉
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    Language: English
    In: Skeletal radiology, 2011-11, Vol.40 (11), p.1391-1397
    Description: Gorham–Stout disease (also known as “disappearing bone disease”) was first described by Jackson in 1838, but was properly defined by Gorham and Stout in a series of 24 patients in 1954–1955. It is a rare disease of unknown etiology (about 200 cases reported in the literature) characterized by spontaneous progressive resorption of bone without malignant proliferation of vascular structures. The diagnosis is one of exclusion and it is based on combined histological, radiological, and clinical features. Benign vascular proliferation with fatty bone marrow and thinning of bony trabeculae is a typical histological feature. Standard radiographs of disappearing bone disease show progressive bony resorption with adjacent soft tissue involvement. Most cases of Gorham–Stout disease resolve spontaneously, but prognosis remains unpredictable. This study reports 13 cases of Gorham–Stout disease treated in our institution from 1968 to 2008. The aim of the work was to review our series and the literature on this rare disease, as well as to evaluate whether or not an optimal treatment can be identified and recommended.
    Subject(s): Pathology ; Gorham–Stout disease ; Medicine & Public Health ; Massive osteolysis ; MRI ; Orthopedics ; Hemangiomatosis ; Vanishing bone disease ; Nuclear Medicine ; Imaging / Radiology ; Osteoporosis. Osteomalacia. Paget disease ; Miscellaneous. Osteoarticular involvement in other diseases ; Radiodiagnosis. Nmr imagery. Nmr spectrometry ; Osteoarticular system. Muscles ; Investigative techniques, diagnostic techniques (general aspects) ; Diseases of the osteoarticular system ; Biological and medical sciences ; Medical sciences ; Humans ; Middle Aged ; Child, Preschool ; Fractures, Spontaneous - etiology ; Male ; Osteolysis, Essential - complications ; Radiography ; Young Adult ; Osteolysis, Essential - therapy ; Bone and Bones - diagnostic imaging ; Adolescent ; Adult ; Female ; Osteolysis, Essential - diagnosis ; Osteolysis, Essential - diagnostic imaging ; Child ; Fractures, Spontaneous - surgery ; Index Medicus
    ISSN: 0364-2348
    E-ISSN: 1432-2161
    Source: Alma/SFX Local Collection
    Source: © ProQuest LLC All rights reserved〈img src="https://exlibris-pub.s3.amazonaws.com/PQ_Logo.jpg" style="vertical-align:middle;margin-left:7px"〉
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    Language: English
    In: Skeletal radiology, 2010-02, Vol.39 (2), p.161-167
    Description: Aneurysmal bone cyst (ABC) is a lytic benign bone lesion representing about 1% of all primary bone tumors. The lesion causes pain and swelling, which are generally present for less than 3 months.From April 2003 to April 2008 36 patients affected by aneurysmal bone cysts were treated by selective arterial embolization with N-2-butyl cyanoacrylate. The study population comprised 20 male and 16 female patients with an age range of 3.3–60.8 years. Nine lesions were localized in the appendicular skeleton (1 in the upper and 8 in the lower limb), 4 in the thoracic cage (1 rib lesion and 3 scapular lesions), 17 in the pelvis and 6 in the spine (1 thoracic and 5 sacral localizations). A total of 55 embolizations were performed: in 22 cases (61%) only one embolization was needed, whilst two embolizations were necessary in 9 cases (25%) and 3 in the remaining 5 patients (14%). The treatment was effective in 32 patients (94% ): follow-up was 0.9–5 years. In one patient, previously surgically treated, only the cyanoacrylate embolization turned out to be useful for healing the lesion. Another 7 patients underwent surgery during the study period. In the 55 procedures we performed we had 3 complications (5%): 2 cases of skin necrosis and 1 of transient paresis.Arterial embolization with cyanoacrylate may be the treatment of choice for aneurysmal bone cysts. Embolization is a less invasive, lower cost, simpler procedure than surgery and is easily repeatable.
    Subject(s): Pathology ; Digital subtraction angiography (DSA) ; Medicine & Public Health ; Orthopedics ; Selective arterial embolization (SAE) ; N-2-butyl cyanoacrylate ; Nuclear Medicine ; Imaging / Radiology ; Tumor-like lesion ; Aneurysmal bone cyst (ABC) ; Cardiovascular system ; Radiodiagnosis. Nmr imagery. Nmr spectrometry ; Osteoarticular system. Muscles ; Investigative techniques, diagnostic techniques (general aspects) ; Diseases of the osteoarticular system ; Tumors of striated muscle and skeleton ; Biological and medical sciences ; Medical sciences ; Humans ; Middle Aged ; Child, Preschool ; Male ; Treatment Outcome ; Bone Cysts, Aneurysmal - therapy ; Young Adult ; Hemostatics - administration & dosage ; Adolescent ; Adult ; Female ; Aged ; Child ; Embolization, Therapeutic - methods ; Enbucrilate - administration & dosage ; Cysts ; Nitriles ; Paralysis ; Index Medicus
    ISSN: 0364-2348
    E-ISSN: 1432-2161
    Source: Alma/SFX Local Collection
    Source: © ProQuest LLC All rights reserved〈img src="https://exlibris-pub.s3.amazonaws.com/PQ_Logo.jpg" style="vertical-align:middle;margin-left:7px"〉
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...